TY - JOUR
T1 - Noninvasive Voice Biomarker Is Associated With Incident Coronary Artery Disease Events at Follow-up
AU - Sara, Jaskanwal Deep Singh
AU - Maor, Elad
AU - Orbelo, Diana
AU - Gulati, Rajiv
AU - Lerman, Lliach O.
AU - Lerman, Amir
N1 - Funding Information:
This study was in part supported by Vocalis Health, Tel Aviv, Israel.
Publisher Copyright:
© 2021 Mayo Foundation for Medical Education and Research
PY - 2022/5
Y1 - 2022/5
N2 - Objective: To evaluate the association between a preidentified voice biomarker and incident coronary artery disease (CAD) events. Methods: Patients referred for clinically indicated coronary angiography underwent a total of three 30-second voice recordings using the Vocalis Health smartphone application between January 1, 2015, and February 28, 2017. A pre-established voice biomarker was derived from each individual recording, and the mean biomarker value was calculated for each patient. Individuals were clinically observed through December 31, 2019. The prespecified primary outcome was a composite of presenting to the emergency department with chest pain, being admitted to the hospital with chest pain, or having an acute coronary syndrome; the prespecified secondary outcome was a composite of a positive stress test result at follow-up or the presence of CAD at follow-up coronary angiography. Results: In the final analysis, 108 patients were included (mean age, 59.47±11.44 years; male, 59 [54.6%]). The median follow-up time was 24 months (range, 1 to 60 months). In multivariable Cox proportional hazards models adjusting for CAD grade on baseline angiography, a high baseline mean voice biomarker was significantly associated with both the primary (hazard ratio, 2.61; 95% CI, 1.42 to 4.80; P=.002) and secondary (hazard ratio, 3.13; 95% CI, 1.13 to 8.68; P=.03) composite outcomes. Conclusion: This study found a significant association between a noninvasive voice biomarker and incident CAD events at follow-up. These results may have important clinical implications for the remote and noninvasive screening of patients to identify those at risk of coronary disease and its complications.
AB - Objective: To evaluate the association between a preidentified voice biomarker and incident coronary artery disease (CAD) events. Methods: Patients referred for clinically indicated coronary angiography underwent a total of three 30-second voice recordings using the Vocalis Health smartphone application between January 1, 2015, and February 28, 2017. A pre-established voice biomarker was derived from each individual recording, and the mean biomarker value was calculated for each patient. Individuals were clinically observed through December 31, 2019. The prespecified primary outcome was a composite of presenting to the emergency department with chest pain, being admitted to the hospital with chest pain, or having an acute coronary syndrome; the prespecified secondary outcome was a composite of a positive stress test result at follow-up or the presence of CAD at follow-up coronary angiography. Results: In the final analysis, 108 patients were included (mean age, 59.47±11.44 years; male, 59 [54.6%]). The median follow-up time was 24 months (range, 1 to 60 months). In multivariable Cox proportional hazards models adjusting for CAD grade on baseline angiography, a high baseline mean voice biomarker was significantly associated with both the primary (hazard ratio, 2.61; 95% CI, 1.42 to 4.80; P=.002) and secondary (hazard ratio, 3.13; 95% CI, 1.13 to 8.68; P=.03) composite outcomes. Conclusion: This study found a significant association between a noninvasive voice biomarker and incident CAD events at follow-up. These results may have important clinical implications for the remote and noninvasive screening of patients to identify those at risk of coronary disease and its complications.
UR - http://www.scopus.com/inward/record.url?scp=85129515928&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85129515928&partnerID=8YFLogxK
U2 - 10.1016/j.mayocp.2021.10.024
DO - 10.1016/j.mayocp.2021.10.024
M3 - Article
C2 - 35341593
AN - SCOPUS:85129515928
SN - 0025-6196
VL - 97
SP - 835
EP - 846
JO - Mayo Clinic Proceedings
JF - Mayo Clinic Proceedings
IS - 5
ER -